Kiora Pharmaceuticals, Inc. (KPRX)
NASDAQ: KPRX · Real-Time Price · USD
2.330
+0.010 (0.43%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Kiora Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
13
Market Cap
10.23M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionKPRX News
- 15 days ago - Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway - Newsfile Corp
- 26 days ago - Kiora Pharmaceuticals Announces Management Team Changes - Newsfile Corp
- 5 weeks ago - Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials - Newsfile Corp
- 2 months ago - Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference - Newsfile Corp
- 3 months ago - Retinal Disease Expert Dr. Taiji Sakamoto Joins Kiora Pharmaceuticals' Scientific Advisory Board - Newsfile Corp
- 5 months ago - Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory Compounds - Newsfile Corp
- 6 months ago - Kiora Pharmaceuticals Reports Third Quarter 2025 Results; Company Advances Pipeline with Two Actively Enrolling Phase 2 Clinical Trials for Retinal Diseases - Newsfile Corp
- 6 months ago - Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders - PRNewsWire